The Supreme Court issued an order on May 15 preserving access to mifepristone by mail while a lawsuit challenging the abortion pill's availability works its way through the courts. The ruling keeps current distribution rules in place and prevents any immediate restriction on the drug, which is used in the majority of abortions in the United States.
The case involves a challenge brought in Louisiana against the Food and Drug Administration's approval of mifepristone and the agency's rules permitting mail-order distribution of the drug. By issuing a stay, the Court blocked lower court restrictions from taking effect while litigation continues, meaning patients can continue to obtain the medication through mail-order pharmacies under existing FDA guidelines.
The order was not accompanied by a full written opinion explaining the majority's reasoning, which is common for emergency stay applications. However, Justices Clarence Thomas and Samuel Alito wrote publicly to criticize the decision, arguing the Court was undermining its own 2022 ruling in Dobbs v. Jackson Women's Health Organization, which returned abortion regulation to the states. Their dissent signals ongoing ideological tension on the Court over abortion-related litigation.
Danco Laboratories, the manufacturer of the brand-name version of mifepristone sold as Mifeprex, had been a party to related litigation seeking to protect the drug's FDA approval. The Court's stay applies while the underlying lawsuit continues, meaning the question of mifepristone's long-term legal status remains unresolved and further court proceedings are expected.
The ruling is seen as a temporary reprieve for abortion providers and patients who rely on medication abortion, which now accounts for the majority of abortions performed in the country. Advocates on both sides of the abortion debate noted that the order does not constitute a final ruling on the merits of the challenge, and the legal fight over the pill's availability is expected to continue for months or years.
Left-Leaning Emphasis
- The Guardian and Vox frame the ruling as a significant victory for abortion access advocates and highlight relief among reproductive rights groups.
- NBC News emphasizes the practical impact on patients, noting that mail access to the pill remains uninterrupted.
- Vox provides detailed context on the Danco Laboratories case and the broader legal strategy by anti-abortion litigants to restrict the drug through regulatory challenges.
- Left-leaning outlets stress that the stay is temporary and warn that the underlying legal threat to mifepristone has not been eliminated.
Right-Leaning Emphasis
- The Daily Wire frames the ruling as a 'blow to the pro-life fight,' emphasizing disappointment among anti-abortion advocates.
- The Federalist centers its coverage on the Thomas and Alito dissents, arguing the majority is actively undermining the Dobbs decision.
- The New York Post uses neutral wire-style language but places the story in the context of ongoing conservative legal efforts to restrict abortion access.
- Right-leaning outlets highlight the dissenting justices' argument that the Court is overstepping its role and setting a problematic precedent post-Dobbs.
Sources
The Guardian, Vox, NBC News, PBS NewsHour, BBC, New York Post, Daily Wire, The Federalist